deferasirox has been researched along with Mucorales Infection in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andes, D; Anglim, A; Bonilla, H; Ibrahim, AS; Mathisen, GE; Perez, M; Spellberg, B; Walsh, TJ | 1 |
| Campos, VF; Cruz, LR; Danilow, MZ; dos Santos, VM; Paixão, GT; Ribeiro, EF | 1 |
| Albert, ND; Kontoyiannis, DP; Lewis, RE | 1 |
| Edwards, J; Ibrahim, AS; Spellberg, B | 1 |
| Edwards, J; Ibrahim, AS; Kontoyiannis, DP; Spellberg, B; Walsh, TJ | 1 |
| Barbui, A; Busca, A; De Rosa, FG; Falda, M; Limerutti, G; Locatelli, F | 1 |
| Brass, EP; Chin-Hong, PV; Fredricks, D; Ibrahim, AS; Kontoyiannis, DP; Morris, MI; Perfect, JR; Spellberg, B | 2 |
| Gupta, N; Rodrigues, C; Shetty, A; Soman, R | 1 |
| Donnelly, JP; Lahav, M | 1 |
| Ibrahim, A; Kontoyiannis, DP; Lewis, RE; Lortholary, O; Petrikkos, G; Roilides, E; Spellberg, B; Walsh, TJ | 1 |
| Edwards, JE; Ibrahim, A; Reed, C; Spellberg, B; Walot, I | 1 |
| Edwards, JE; French, SW; Fu, Y; Gebermariam, T; Husseiny, MI; Ibrahim, AS; Lin, L; Schwartz, J; Skory, CD; Spellberg, BJ | 1 |
2 review(s) available for deferasirox and Mucorales Infection
| Article | Year |
|---|---|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbial Viability; Mucorales; Mucormycosis; Pyridones; Triazoles | 2008 |
Recent advances in the management of mucormycosis: from bench to bedside.
Topics: Amphotericin B; Antifungal Agents; Benzoates; Case Management; Clinical Trials as Topic; Deferasirox; Drug Therapy, Combination; Echinocandins; Humans; Immunologic Factors; Mucormycosis; Polyenes; Triazoles | 2009 |
2 trial(s) available for deferasirox and Mucorales Infection
| Article | Year |
|---|---|
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
Topics: Adult; Aged; Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Mice; Middle Aged; Mucormycosis; Placebos; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Risk factors for mortality in patients with mucormycosis.
Topics: Adult; Aged; Amphotericin B; Benzoates; Deferasirox; Double-Blind Method; Ferritins; Humans; Iron; Kaplan-Meier Estimate; Lung Diseases; Middle Aged; Mucor; Mucormycosis; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2012 |
9 other study(ies) available for deferasirox and Mucorales Infection
| Article | Year |
|---|---|
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
Topics: Adult; Aged; Benzoates; Chelation Therapy; Deferasirox; Exanthema; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Mucormycosis; Treatment Outcome; Triazoles | 2009 |
Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen.
Topics: Adult; Amphotericin B; Antifungal Agents; Benzoates; Bone Marrow; Deferasirox; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Immunophenotyping; Karyotyping; Leukemia, Myeloid, Acute; Mucormycosis; Nucleophosmin; Treatment Outcome; Triazoles | 2013 |
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus fumigatus; Benzoates; Caspofungin; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mucormycosis; Neutropenia; Rhizopus; Treatment Outcome; Triazoles | 2014 |
The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.
Topics: Amphotericin B; Antifungal Agents; Benzoates; Caspofungin; Deferasirox; Echinocandins; Fatal Outcome; Female; Humans; Iron Chelating Agents; Lipopeptides; Lung; Lung Diseases, Fungal; Middle Aged; Mucormycosis; Rhizopus; Stem Cell Transplantation; Tomography, X-Ray Computed; Triazoles | 2012 |
Deferasirox in mucormycosis: hopefully, not defeated.
Topics: Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Mucormycosis; Triazoles | 2012 |
Deferasirox as adjunctive therapy for mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Mucormycosis; Triazoles | 2012 |
Combination therapy for mucormycosis: why, what, and how?
Topics: Animals; Antifungal Agents; Benzoates; Clinical Trials as Topic; Deferasirox; Drug Therapy, Combination; Echinocandins; Humans; Lipids; Mice; Mucormycosis; Polyenes; Treatment Outcome; Triazoles | 2012 |
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
Topics: Adult; Amphotericin B; Antifungal Agents; Benzoates; Brain Stem; Caspofungin; Cavernous Sinus; Central Nervous System Fungal Infections; Deferasirox; Diabetic Ketoacidosis; Drug Therapy, Combination; Echinocandins; Humans; Iron Chelating Agents; Lipopeptides; Magnetic Resonance Imaging; Male; Mucormycosis; Nose Diseases; Peptides, Cyclic; Salvage Therapy; Triazoles | 2006 |
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Topics: Amphotericin B; Animals; Benzoates; Deferasirox; Diabetes Mellitus; Drug Therapy, Combination; Iron; Iron Chelating Agents; Liposomes; Male; Mice; Mice, Inbred BALB C; Mucorales; Mucormycosis; Survival Rate; Th1 Cells; Th2 Cells; Triazoles | 2007 |